企业高质量发展的背后，离不开税收政策的有力支持。而要让好政策落地，让纳税人缴费人真真切切地享受到政策红利，则离不开税务部门的创新服务。 2024年，全省落实支持科技创新和制造业发展减税降费及退税3185亿元，约占全国八分之一;落实外商投资企业利润再投资优惠政策吸引再投资354亿元， 成效连续7年保持全国第一；通过"银税互动"帮助50.6万户企业获得信用贷款3419.4亿元……江苏税务部门持续扎实推进税收营商环境建设。 近日，"'赢'在江苏——寻找2025优化营商环境新实践"全媒体采访团走进国家税务总局江苏省税务局，采访多家受惠企业，探寻我省税务部门以创新服务 优化营商环境的最新成果。 税费政策精准推送，确保科技企业享受红利 从"人找政策"转变为"政策找人"，持续深化税费政策精准推送机制，江苏税务部门的服务让我省科技企业及时享受到国家税费政策红利。 【工作亮点】 "让税费政策更直达、更快享，江苏税务运用税收大数据，主动甄别、精准定位符合享受优惠政策条件的企业，向其推送涵盖税费政策、操作指引、服务 渠道等内容的个性化政策'大礼包'。"江苏省税务局纳税服务处夏建军介绍，江苏税务还建立了"未诉先办、接诉快办、遇诉好办 ...

Johnson & Johnson (JNJ) 2025 Conference Summary Industry Overview - The healthcare industry is currently facing unprecedented challenges related to tariffs and policy changes, impacting growth expectations for many companies [3][4] - Johnson & Johnson is committed to investing $55 billion over the next four years, representing a 25% increase, primarily influenced by tax policy changes [8] Key Financial Insights - In Q1, Johnson & Johnson absorbed an estimated $400 million impact from tariffs, primarily affecting the med tech segment, but this impact has since been reduced to approximately $200 million due to changes in the tariff landscape [5][6] - The company reported a 4% growth in Q1 despite losing a significant product, Stellar, which had a $10 billion market value [27] Innovative Medicine Segment - Johnson & Johnson's innovative medicine segment is projected to grow at a CAGR of 5-7% from 2025 to 2030, driven by transformative drugs [30][34] - Key products include: - Tremfya for psoriasis, projected to generate $4 billion by 2027-2028, with expectations of 25% higher sales than market estimates [23][24] - Ribrovant for lung cancer, anticipated to exceed $2 billion in the same timeframe, with potential for improved patient outcomes [24] - New oral formulation for psoriasis, expected to file for approval later this year [25] - A promising bladder cancer treatment projected to significantly outperform analyst expectations [26] Med Tech Segment - The med tech segment is also expected to grow at a CAGR of 5-7% from 2023 to 2028, although current performance is not meeting expectations [34] - Key developments include: - Progress in wound closure and biosurgery, with advancements in the OTAVA robotic surgical solution [35] - Strong uptake of the Vellus knee solution, with expectations for mid-single-digit growth in orthopedics [36] - Continued leadership in vision care, with plans to reinvigorate growth through commercial efforts [38] - Challenges in electrophysiology (EP) due to increased competition and regulatory pauses, but efforts are underway to regain market position [39][42] Pricing and Access Issues - Johnson & Johnson's average net price has decreased by 3-4% annually over the past six years, limiting pricing power [22] - The company emphasizes the need for discounts and rebates to reach patients effectively, with an average discount of 55-60% off list prices in the U.S. [14][15] - Access to oncology drugs in the U.S. is significantly higher than in other G20 countries, highlighting the importance of maintaining access to innovative treatments [16] Litigation and Financial Management - The company has reversed a $7 billion accrual related to talc litigation, expressing confidence in its legal position and financial stability [49][52] - Johnson & Johnson generates $20 billion in free cash flow, allowing for continued investment in R&D and acquisitions despite litigation risks [52] Investor Outlook - Johnson & Johnson is positioned as a reliable investment with significant growth potential in the second half of the decade, despite current headwinds [55] - The company is focused on delivering sophisticated treatments and maintaining investor returns [55]

Otter Tail (OTTR) Q1 2025 Earnings Call May 06, 2025 11:00 AM ET Company Participants Tyler Nelson - VP - Finance & TresaurerCharles MacFarlane - President and CEOTodd Wahlund - VP & CFO Conference Call Participants Sophie Karp - Managing Director & Equity Research Analyst Operator Good morning, and welcome to Otter Tail Corporation's First Quarter twenty twenty five Earnings Conference Call. Today's call is being recorded. We will hold a question and answer session after the prepared remarks. I will now tu ...

Otter Tail (OTTR) Q1 2025 Earnings Call May 06, 2025 11:00 AM ET Company Participants Tyler Nelson - VP - Finance & TresaurerCharles MacFarlane - President and CEOTodd Wahlund - VP & CFO Conference Call Participants Sophie Karp - Managing Director & Equity Research Analyst Operator Good morning, and welcome to Otter Tail Corporation's First Quarter twenty twenty five Earnings Conference Call. Today's call is being recorded. We will hold a question and answer session after the prepared remarks. I will now tu ...

Otter Tail (OTTR) Q1 2025 Earnings Call May 06, 2025 11:00 AM ET Speaker0 Good morning, and welcome to Otter Tail Corporation's First Quarter twenty twenty five Earnings Conference Call. Today's call is being recorded. We will hold a question and answer session after the prepared remarks. I will now turn the call over to the company for their opening comments. Speaker1 Good morning, and welcome to our first quarter earnings conference call. My name is Tyler Nelson. I'm Otter Tail Corporation's Vice Presiden ...